Startups
We are experts in developing novel sub-unit vaccines
Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner.
Our current portfolio comprises 6 vaccines across livestock species.
Proof of concepts have been generated in > 20 additional vaccine antigens
Value through collaborations
Our go to market strategy is inherently linked to collaborations. We offer:
• Development of tailor-made baculovirus vectors optimized for industrial production.
• Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®.
• Supply of recombinant proteins produced in CrisBio® through license agreements.
• Development of proprietary portfolios.
Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.
Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner.
Our current portfolio comprises 6 vaccines across livestock species.
Proof of concepts have been generated in > 20 additional vaccine antigens
Value through collaborations
Our go to market strategy is inherently linked to collaborations. We offer:
• Development of tailor-made baculovirus vectors optimized for industrial production.
• Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®.
• Supply of recombinant proteins produced in CrisBio® through license agreements.
• Development of proprietary portfolios.
Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.
Overview
Location
Spain, Community of Madrid, Tres Cantos
Employees
11-50
Founded date
2005
FAQ about ALGENEX S.L
When was ALGENEX S.L founded?
ALGENEX S.L was founded in 2005.
Is ALGENEX S.L still active?
ALGENEX S.L is probably closed.